June 12, 2026 - 04:24

Phil Orlando, Chief Market Strategist at Federated Hermes, kicked off his talk at the INSITE 2026 conference by looking back at history. He noted that from Eugene Black in 1933 to current Chair Jerome Powell, there have been eleven leadership changes at the U.S. Federal Reserve. In every single case, Orlando argued, the market put the new chair to the test. "The market hits a rough patch, tests the new leadership," he said, suggesting a period of volatility may be ahead.
Despite the cautious tone, Orlando stopped short of calling the current market a bubble. He described the situation as "overvaluation, not a bubble." This is a key distinction. A bubble implies a speculative frenzy that is about to burst, while overvaluation suggests prices are high but can correct in a more orderly fashion.
Orlando specifically pointed to technology stocks as being at risk. He predicted they could fall as much as 20% from current levels. This would represent a significant correction for a sector that has driven much of the market's recent gains. His warning comes as investors debate whether the AI-driven rally has gone too far and whether interest rates will stay higher for longer than many expect.
September 30, 2026 - 01:50
Space Force Turns to Laser Systems to Shield Launch Sites from Drone ThreatsThe U.S. Space Force is moving forward with plans to deploy laser technology as part of a broader effort to defend its launch facilities from unauthorized drones. The initiative focuses on...
September 29, 2026 - 04:58
DIU Seeks Investors in Counter-Unmanned Systems TechnologyThe Defense Innovation Unit is looking for private investors to back companies working on counter unmanned systems technology. The effort targets firms building tools to detect, track, and disable...
September 28, 2026 - 02:02
Novo Nordisk (CPSE:NOVO B) Secures Long-Acting Injectable Technology In €1.165 Billion Nanexa Licensing AgreementNovo Nordisk has entered a global licensing agreement with Swedish drug delivery company Nanexa, valued at up to 1.165 billion euros. The deal centers on Nanexa`s PharmaShell technology, a platform...
September 27, 2026 - 08:32
New Biochip Enables Real-Time Tracking of Parkinson's Treatment ResponseResearchers have created a biochip technology that allows for real-time monitoring of how Parkinson`s disease patients respond to treatment. The development comes from a team working on advanced...